Fig. 2.

Kaplan-Meier curve for the risk of (A) progression to ESRD and (B) AKI before the propensity-score matched cohorts treated with H2B (solid line) or PPI (dotted line) in pre-ESRD patients. Kaplan–Meier curve illustrating the cumulative incidence of (A) progression to ESRD and (B) AKI in per-ESRD patients newly prescribed proton pump inhibitors (PPIs) and histamine-2 receptor blockers (H2B). We followed up new users of PPI or H2B to be on therapy until the censor points, which are the first occurrence of any study outcome within 1 year, death, end of year 2018, or follow up duration until 1 year, whichever came first. A visual inspection suggests that risk of progression to ESRD and AKI seems to be higher in PPI users, compared to H2B users. AKI, acute kidney injury; ESRD, end stage renal disease